This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
Operator
Good morning and welcome to the ProPhase Labs second quarter 2022 financial results and corporate update. All participants will be in listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star, then one on a touchtone phone. To withdraw your question, please press star, then two. Please note, this event is being recorded. I would now like to turn the conference over to Ted Karkas, CEO and Chairman of the Board of ProPhase Labs. Please go ahead.
Ted Karkas
Thanks so much. Thank you all for joining me today. Before we start, unfortunately, I have to read the forward-looking statement. I'll read it quickly. I think you all know what it is. Before we begin Today's call, I want to advise everyone that today's conference call will contain forward-looking statements, including statements relating to our plans, expectations, future performance, and future events, including statements regarding projected financial results for the third quarter of 2022, our expectations regarding the COVID-19 pandemic, future waves of the pandemic and continued demand for diagnostic testing, HRSA funding, that's HRSA funding, our plans to grow our diagnostic business and expand our lab services, our plans to grow our genomics businesses, our plans to develop Linebacker and Equivir, and our expectations regarding the sufficiency of our cash and working capital. These statements are subject to risks and uncertainties that could cause our actual results to differ material from those suggested by the forward-looking statements. Additional information concerning factors that could cause our results to differ materially from these forward-looking statements are contained in the earnings release that we issued earlier today, as well as in our public filings with the SEC. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except to the extent required by applicable law. Finally, a conference call is being webcast. The webcast link is available in the investor relations section of ProfaseLabs.com. Thank you, Wendy Grosso, our amazing securities attorney, for putting together my forward-looking statement. All right. Now that I have that away, welcome all. I really appreciate you joining. I really appreciate your support and interest in our company. It's always hard for me to gauge whether there are some new investors on the call and to what extent I should address them as opposed to our longer term investors and analysts and so forth. A couple of quick things just to point out for those that aren't aware. Um, first of all, I have these two great investment banks that we work with think equity and AT Wainwright. They both, uh, cover our company, uh, from an analyst point of view. Uh, but in addition to that, um, they're fantastic companies to work with. I have 40 years of experience working on wall street, working investment banking firms. And so I made sure, uh, I had a, I had a choice of a hundred. That might be an exaggeration, but a choice of dozens. of investment banks to work with. It's critically important when you're a development stage company to have the right relationships with the right investment bankers, and we certainly have those. I should also mention, and that's more on the institutional side, but I should also mention on the retail side, we work with Renmark, which is actually a Canadian company, but they do a fantastic job. They set up virtual non-deal roadshows for us. I've been doing those. roughly every week, two weeks, three weeks. You can contact Redmark if you're ever interested. I do presentations that review the latest. It's basically an overview of the company as well as, you know, any information that's public. I'm always doing a review and a recap. Some of our long-term shareholders love those calls, even though it is primarily the purpose of it is for new investors. I should also point out that on our website, we actually have two slide presentations now. One is for the overview of the company as a whole for prophase labs and its five subsidiaries, and then we have a separate approximate 30-page slide presentation just on prophase biopharma. I promise you, we would not have put all that work into that slide presentation and gone through all of this if I didn't think that it had significant potential. I will get to that momentarily. I do want to keep this call short. The second quarter earnings release does speak for itself. We are one of the few development stage companies out there that actually earns money. All right. And we earn it every year, you know, every quarter and our, and our numbers continue to grow year over year and our working capital grows quarter to quarter and we pay dividends and we make acquisitions. Please somebody on this call, Find me one company out of the 10,000 NASDAQ companies in the universe, you know, they're not all microcap, but find me any microcap company that can claim to have done all the things that we continue to accomplish. Because I can't find one that can grow, that can make smart new acquisitions so that we have a future while at the same time earning money in the present. It's a rare combination. I don't take all the credit for it. We have a team that's really fantastic. And, you know, let me get into a couple of things. I don't have a lot of prepared remarks. I do these presentations every few weeks or even more often with Renmark. And the numbers do speak for themselves. And I do want to get to the Q&A early. I don't want to have a long call just to listen to me talk. So a couple of things I do want to point out. First of all, prophase diagnostics. We got slammed with a curveball in the second quarter. Uh, when we found out at the end of the first quarter that HRSA, HRSA, uh, funding, they had run out of funding. This is the government funding that was paying for people without insurance to get tested. We kept hoping that it was going to come back. It didn't. Um, I give actually Jason Karkas, uh, not a coincidence. We have the same last name. He is my son. Um, he took the reins and pivoted our business. so that we could be more insurance-oriented. We were probably, this is a rough estimate, around 70% uninsured going into the second quarter. And he pivoted and worked very closely with our chief information officer, Sergio Morales, who does an absolute phenomenal job with our IT. And they developed together a better IT platform that could actually pick up insurance on the spot. And so we, in any event, we pivoted very quickly and understand, you know, a lot of our business comes from concierge services and from tents on the street. You know, these are people walking up to a tent. So for us to have a sophisticated IT platform at a tent that is being removed on a daily basis, I promise it's no easy feat. And so we actually brought a lot of sophistication, you know, to a business, to a tent that isn't in and of itself particularly sophisticated. So I give them an enormous amount of credit because basically 70% of our business went away overnight and it did so during our seasonally weaker quarter. And yet we still have these phenomenal results. So I give the two of them an enormous amount of credit. And so Jason has been promoted to president. It's well-deserved. He's responsible for building the revenue base of the company to just an extraordinary amount of revenues. So he has a very bright future at the company. He's doing a phenomenal job. And Sergio has built an absolute beautiful state-of-the-art IT platform. So we are in great shape. I would then also like to highlight that Alice Leoy was also promoted to, in addition to being COO of Prophase Diagnostics, she's also COO of our newly formed division, wholly owned subsidiary, Prophase Biopharma. She was instrumental, really integrally involved, led the charge in the compounds that we licensed and in developing the relationships with the teams that invented these compounds and that we licensed these compounds from. She's really taken the lead on all of this. It's really exciting. We think that Prophase Biopharma has enormous upside potential. And I'll get into that a little more, but I just wanted to highlight some of the people behind the scenes that really did a fantastic job for us. I should also mention that we hired Bill White. I believe we hired him during the second quarter. So it is the second quarter highlight. He is our new CFO. He's really integrated himself well into the company. He works incredibly well with Monica Brady, who continues as both chief accounting officer of the parent company as well as CFO of ProPhase Diagnostics. They're really working well together. We're building the team further. We've hired an additional controller. We have another controller coming on board. We're really building up the finance department, so I've never felt better. And Bill is gonna work with Monica in taking our company You know, Monica helped take our company from a $10 million company to a $100 million company to a $200 million company. Now we want to take it to a billion or multi-billion dollar company. And I believe Bill can help get us there. So that's just touching the surface on our team. We really have a fantastic team here. And at the end of the day, what I want to go back to, and this is going to be a little bit of a rant, at the end of the day, and I know I've told this story before, but in micro-cap companies, the most important thing is investing in the management team. It's what I learned 30 and 40 years ago. It's what Warren Buffett has said for 40 years. But the truth of the matter is so difficult because what happens is you get excited about the product or the service, not the management team. And every management team is optimistic about the product. And so it's critically important from an investor point of view to pay attention to, do you have a management team that executes? But it's often hard because with startup companies, you often have startup management teams. So this is just another situation where Um, if you're invested in a company, you're investing in a management team that has, uh, you know, proven track record of success year after year, after year, after year. Um, and look, we don't always know what the future is going to bring. We don't, we didn't know that all of a sudden HRSA wasn't going to be funded and we, you know, 70% of our business was going to disappear. All right. But we responded and other labs didn't. And so we, we run circles around other labs. We have more sophisticated. Technology, IT, we have more sophisticated equipment. We're much more efficient in processing. We don't lose, knock on wood, I don't think we've ever lost a customer. Our customer base continues to grow. And COVID isn't going anywhere. Next, I would just mention, we go through waves of COVID. Going back a year ago, everybody thought we would have COVID for a period of time. It would go away. And that we'd be a one trick wonder. Well, guess what? COVID is not going anywhere. It continues to mutate. I said three months ago, watch out for BA4, BA5. It's now accelerating in this country. And this is during what I consider to be our off season for COVID testing. And yet we're still earning an enormous amount of money. And by the way, we're earning money in the third quarter too. And again, last year at this time, you know, I think we lost money in the second and third quarter. Certainly on an earnings basis, on an adjusted EBITDA basis, between the two quarters, we were probably about break even. So it just gives you an idea of the execution of the company. And let's now, I just want to briefly, look, the quarter speaks for itself. I'll highlight maybe just a couple of things in the quarter in terms of the numbers. Just so you should be aware, first of all, between the fourth quarter of last year, fourth quarter last year, and first quarter this year, we did over 90 million in revenues. When you now include the first quarter, you know, almost 30 million revenues, we're talking about about $120 million in revenues just in the last three quarters. Earnings, fourth quarter, 10.6 million in earnings. First quarter, 12.5 million in earnings. And now, you know, This quarter, and I apologize, net income of another $7.4 million in earnings. And then a number I really like to focus on is adjusted EBITDA because adjusted EBITDA takes out all of the non-cash charges. A lot of these are expenses that later get reversed. But regardless, our EBITDA over the last three quarters is $43 million. It's almost $3 a share in EBITDA. It's undeniable. Um, so anyway, that's the execution of our company. Um, I'm looking for this, uh, in the fourth quarter of this year, we'll be testing not only for COVID, but also, uh, for flu and upper respiratory. We are looking, I know we always get questions about monkeypox. It's complicated. Uh, we are looking to validate for monkeypox, but you have to put this in perspective, you know, um, the number of people that are actually going to be tested for monkeypox pales in comparison to the number of people that are being tested for COVID. And especially once we get into flu season and people don't know if they have flu or COVID, guess what? They're going to rush to get COVID tested. And that's regardless of which variant happens to be, you know, around at that time. So that's a little bit about prophase diagnostics. Again, we are diversifying our prophase diagnostic business. We're going to get into full clinical. We're going to be a well-diversified diagnostic testing company in the future. In parallel, we are planning on the build-out of a genomics lab as well. So then we'll really be a fully diversified diagnostic company that's doing, you know, high-complexity molecular lab testing for upper respiratory, doing, you know, your full blood urinary toxicologies and so forth, and then also a full array of diagnostic genomics testing. So that's on the lab side. Let's talk about Nebula genomics just for a moment. I just want to put this into a little bit of perspective. Nebula is growing off of a small base, but it is growing. It takes time for us to negotiate major deals for lower-priced whole genome sequencing. We do believe we are the low-cost offeror of whole genome sequencing in the country. I'm not going to explain what whole genome sequencing is, but if anybody's confused, you can ask in the Q&A. But again, not only are we offering it at the lowest price, I believe that only a couple percent of the country even knows what whole genome sequencing is. We believe that there is a massive opportunity to educate consumers about whole genome sequencing, where you're getting whole genome sequence, not for ancestry information, but for health related information. And there's always a growing interest in our country for people who are interested in their health and becoming healthier. And it all starts with learning about your personal genetic makeup, which in turn can help you lead you into leading a healthier lifestyle based on diseases that you may be predisposed to. And then if you happen to get a disease in the future, analyzing your genetic makeup to help physicians determine what is the best course of treatment for your disease. That's basically what whole genome sequencing is all about. The first step in that is getting whole genome sequenced. We do provide whole genome sequencing direct to consumers online. We are working at a feverish pace. to offer whole genome sequencing in retail stores. All the major retailers are interested. We're fine-tuning that. It is not a short-term proposition, but that's all going extremely well. And so we have a business here in Nebula, which, and understand, whole genome sequencing is in the first inning, similar to where the Internet was 20 years ago. And we are so well positioned, we have one of the leading authorities in the world over the last 20 years in genomics and George Church, a PhD at Harvard University. And he's a founder and a shareholder of our company. He's on our advisory board. I'm telling you, we are so well positioned. And I only point this out relative to the fact that there's several other companies now in the same space. One raised $18 million. at, we believe, around a $50 million valuation. Another company, and it's not yet public yet, they've raised some money, but they're raising more. And it looks like they're going to be raising approximately $20 million at closer to $100 million valuation. And I believe that our company is significantly more developed than either of those companies. And yet, Nebulant Genomics is valued at so very little in regard to our market cap. So I just want to give you that perspective that Nebula has enormous potential. If this was a Silicon Valley startup where venture capital was just investing in a private round, I'm probably sure the valuations would be significantly greater than what anybody is valuing Nebula in our market cap. So that's a little bit on Nebula. And then I want to talk about ProPhase Biopharma. There was a lot of confusion in the last month when we announced the developments here. I cannot tell you how excited I am about prophase biopharma, uh, Alice Leeway, uh, and our legal team, uh, did an enormous amount of due diligence. Uh, we work with these companies with global research and development group. We've been working with them for two years. Um, and so this isn't something where I just quick came up with an idea overnight to announce, you know, a deal and this particular deal to license linebacker one and two. This was six months in the making. And what I can tell you is the major university did significant preclinical research on these compounds and came back with great results. We just had a conference call with them the other day. They went extremely well. They want to continue to work with us. They're really excited. And so we're just working out the details on that now. Linebacker in a nutshell. And so first of all, I just want to put this in perspective. This is something where we paid virtually nothing up front. I think we paid $50,000 in licensing fees. I paid more in legal fees than I did in licensing fees. These are compounds that I believe we can get through the animal studies and the first human clinical study within about 12 to 18 months at a cost under $5 million. We earn more than that in our seasonally weaker second quarter. So how, how anybody could come away with a conclusion that this is somehow going to impact the value of our company, or that all of a sudden out of the blue, after knowing me for 12 years of running our company, that all of a sudden I'm going to burn through our capital. It's just a ridiculous conclusion. Um, and so I've said publicly now, uh, we're going to, our budget is under $5 million. We have over $50 million in networking capital today. And that's after acquiring and developing Nebula. It's after licensing and building Prophase Biopharma. It's after building a state-of-the-art laboratory facility with I don't know how many millions of dollars of equipment and so on and so on and so on. And then, of course, all the dividends that we paid out. So I really believe that myself and our management team have executed in all facets, everything that you could ask of a management team, I believe that we have delivered and then some. And I'm simply pointing out the best is yet to come for long-term shareholders. You know, I'm sure it's going to be bumpy when you're a development stage company, but understand we're developing products and assets and subsidiaries with absolutely enormous potential. The last thing I want to mention is we've been at a bear market for a year and a half. Nobody realized we were in a bear market until the beginning of the year. But microcap and biotech and life science companies have been in a bear market since January or February of 2021, almost a year and a half. And so I've been pointing out to everybody who has been so bearish the last few months, I've been pointing out that because we've been in a bear market for a year and a half, the life science companies don't be so sure that they're going to continue to drop. And if you've noticed, actually, in the last one to two months, biotech and life science companies have actually led the charge on the upside that's no accident all right uh you know bear markets the stock market um you know discounts the future it doesn't you know discount the past it discounts the future and so it's interesting just in the last week there have been a number of deals in the biotech and life science space and i'd like to just bring your attention to a couple of them As I mentioned, there are at least two genomics companies, startup genomics companies with valuations, one around $50 million, one around $100 million that are raising capital. There have been two deals announced, at least two. One, Gilead is buying Microbio for $405 million. All of their assets are either preclinical or I believe they have one asset going and just starting to go into phase one. And they're being acquired for $405 million. And so that's why I tell you we have a potential major breakthrough in cancer research with the compounds that we are developing. And I believe that we could be at the same stage of development in 12 to 18 months from now. And then, of course, Amgen paying $3.7 billion for chemocentrics. There were major deals starting to happen, and the market's starting to wake up, and that's why you see biotech and life science companies are starting to wake up. So it's just an interesting trend. We're in the right place at the right time. And in the meantime, we have a diagnostic business where we're literally just killing it. So with that, I'd really like if people want to ask questions, I'd love to have a lively Q&A if the shareholders want. When we do the Renmark presentations, that is almost all new investors, so they always have a lot of questions. Hopefully we get some questions today, and I'm happy to talk more about any subject. I'm an open book. I am a hands-on CEO. I'm involved in every aspect of our company, so feel free to ask away. And so back to MJ. If you want to open it up to the Q&A, I would appreciate that.
Operator
Thanks so much, Ted. At this time, we'll begin the question and answer session. To ask a question, you may press star then 1 on your touchtone phone. If you're using a speakerphone, please pick up your handset before pressing the keys. If at any time your question has been addressed and you would like to withdraw your question, please press star then 2. Our first question today comes from Yi Chen of HC Wainwright. Please go ahead.
Ted
Thank you for taking my questions. Could you give us a little bit more color on the potential top line growth in the third quarter? Is it going to be on a similar level as the revenue in the second quarter, or is it going to be trend down a little bit, but still exhibit a yearly growth over the third quarter of last year?
Ted Karkas
Here's what I can tell you. Historically, the third quarter is our weakest quarter. that's even been throughout history when we had the Colby's brand and we still do have a lozenge manufacturing facility. Um, and you know, if you think about it, people are buying lozenges, you know, in October, November, December, January, February. So there are, you know, there isn't a lot of activity, uh, in the middle of summer months and the same as, as really been true with COVID. Um, if, uh, not, not to, you know, besides the waves in COVID, but also, uh, You know, you don't have flu and colds as much in the summertime, so there isn't as much confusion over whether you have COVID or you have a cold. So it's just natural, I would say, going forward. I would even predict this into next year. I would say that the middle summer months are always going to be our weakest months for our business, both for COVID testing as well as in our lozenge manufacturing business. But at the same time, I would point out that we're in an interesting situation now whereby all the rules have been relaxed around COVID. Nobody's wearing masks. And more importantly, last year, you still had people being homeschooled. You had students staying at home. I'm not hearing any of that now. All the schools are reopening. Nobody's wearing masks. And so guess what? There's going to be an enormous amount of school testing, but that school testing We'll start, you know, maybe the very last week of August, you know, and into September when we're getting into, you know, the fourth, you know, as we go into the fourth quarter. So I would expect a strong fourth quarter. I would say that third quarter will likely be less than second quarter in terms of revenues and earnings. But let's be very clear here. We're still earning a lot of money on a daily basis. And so our third quarter is, We're going to have a very strong third quarter, and I expect to, year over year, our third quarter to be significantly greater than our third quarter of last year. So, you know, I said this six, nine months. I actually said this nine months ago. I said before we reported the fourth quarter of 2021, that for the next four quarters, our numbers are going to be up year over year significantly, and they have been every single quarter, and they continue to be. So our fourth quarter is up, our first quarter, our second quarter, and I am consistent with that, and I continue to believe that. Our third quarter is going to be up significantly year over year. We're going to be very profitable, but you can assume it's going to be less than the second quarter simply because the middle summer months are the slowest months of the year, and the school season is really only catching the end of the third quarter. But so as we go into the end of the third quarter, the numbers are going to start growing pretty significantly. And then as we get into the fourth quarter, of course, I would expect sequentially the numbers are going to be going up again.
Ted
So for the upcoming school year, do you expect the schools to test all students regardless of whether they have symptoms or not, or just students have symptoms?
Ted Karkas
Yes. Everything I'm hearing, and this is still premature, and it's on a school-by-school basis, but I can tell you, and I've explained this to shareholders before, we have our customers are our specimen collection partners, and we have one or two specimen collection partners in particular that specialize in the schools. And all indications from them are that there's going to be a lot of activity with the schools coming up. In fact, we're ramping up for that right now, and we're working with them right now. And so, yes, I expect there to be a lively amount of COVID testing in the schools, you know, certainly the end of the third quarter into the fourth quarter. I don't know exactly what the numbers are going to be, but it's going to be robust.
Ted
So going forward, the lack of HRSA funding should have minimum impact on your revenue collection going forward?
Ted Karkas
Well, if it was going to have impact, it would have had impact on the second quarter. All right. So whatever impact it had, it had. As far as I'm concerned, you know, we're planning for HRSA not coming back. But with it not coming back, look at how much money we just earned in the second quarter. And now in the third quarter, we're going to be very profitable in the third quarter without it. So I'm assuming it's not coming back, but whatever impact it had, it had, we pivoted. We have a sophisticated IC platform for not only collecting patient data, but also in particular, collecting the insurance information and not only collecting the insurance information, but also checking on the validity of the insurance information, which is key. And so, While 70% of our business before was HRSA funded, that all went away. We've become more sophisticated, and so we're very profitable in the business we're doing. The total number of tests we're doing, you know, the run rate is obviously going to be less, you know, if we're not testing the people that are uninsured. But we're much more sophisticated in collecting the information of the people that are so that we get reimbursed for them, and those numbers are, you know, trending, are stronger.
Ted
Got it. And with respect to the personal genomics business, shall we still expect some significant marketing event to occur before the end of this year?
Ted Karkas
Well, by marketing event, there's – oh, my goodness. There's really two or three things. One is getting into retail stores. The retailers are – have been very receptive and – The complicated part of this actually isn't the retailers. The complicated part is the logistics on where we're doing the whole genome sequencing and what price we're doing in that. We are negotiating, and I think I've mentioned, I know I've mentioned before, we're negotiating with a company in the UAE, and this is a multi-billion dollar company, and they love us. They don't have a presence in the United States, and they want to work with us. And so you'll hear more about that in the coming months. There's not a doubt in my mind about that. But then in addition to that, we're also coordinating our efforts with regard to doing the whole genome sequencing at a lower price. This company does, you know, like 10 times as much whole genome sequencing as anybody else in the world. So they can provide us with the best pricing. So we're working on that. They also want to work with us on building a lab in the United States that does whole genome sequencing. So there's some complicated factors There are two, there's really Illumina is the only company in the United States. They have sort of a monopoly on whole genome sequencing this year. And they're at very high prices. And that's why we're forced to work with international companies. But the patents that the monopoly sort of goes away in January of next year. And so their biggest competitor will be entering the United States. And we expect the pricing dynamic to change dramatically. And then that makes things more complicated because I don't want to enter, a long-term agreement for whole genome sequencing with one of these companies, and then find out in January of next year the pricing drops below our long-term contract. And so that's why I'm just giving you a taste of how complicated things are, which is also a reason why shareholders need to bet on a management team that actually, you know, can work through these complicated details, and that's what we're doing. Having said that, I'm very confident we're going to be dropping the pricing of whole genome sequencing. I am very confident that we're going to be providing whole genome sequencing in major retailers. I am very confident that we are going to be working on strategic relationships with other major companies. And when you put that all together, you know, the market cap of Nebula could be worth more than the entire market cap of our company. And this is a company that has over $50 million in networking capital. And the reason I say that is I'm just looking at – And I call them competing companies, which are not really competing companies. Uh, there are two companies out there that are startup companies that are, one of them is actually completely copied out the story of our business model. It's just a story. And they have a, they have a, uh, they have a, I've, I've been told they have a $50 million market cap pre money. And then there's another one with a hundred million. So it's really interesting, but there's huge potential here. We have international companies that are very interested in Nebula. And so I would expect before year end, we will have at least one, if not two significant developments in Nebula. And I would expect when we go into next year, the perceived market value of Nebula is going to be dramatically greater than it is now. Okay. Thank you. Thank you, Yi. And again, a shout out to Yi Chen and A.T. Wainwright, who does a fantastic job of following our company. I really appreciate it. If we could go to the next caller. That has a question, please.
Operator
Of course. The next question is from private investor Patrick E. Patterson. Please go ahead.
Ted Karkas
Hello, Ken. Can you hear me? I can hear you just fine, and I love the E. I would hate for you to introduce yourself without the E in the middle.
Ken
Look, Ken, you and your team have executed...
Ted Karkas
Patrick, you broke up. I think I lost you.
Operator
It appears that we have lost Patrick. We can go to the next question.
Ted Karkas
Thank you, please.
Operator
Which comes from Dennis Waldman of Barrett Productions, LLC. Please go ahead.
Dennis Waldman
Hi, Ted. All I can say is wow. Congratulations on a fantastic quarter. It was much better than my highest expectations. I do have two questions. First, for 2021, you made 41 cents. For the first six months of this year, you've already done $1.29. So for 2022, I don't see you making anything less than $2 a share. That's five times what you did last year. Yet our stock is just selling at six times PE. What are your plans to bring more visibility to ProPhase in the investment community?
Ted Karkas
All right, that's a great question. I really like the way you calculated those numbers. I personally like to focus on EBITDA more than earnings. And when you focus on EBITDA, the numbers are even greater. In fact, they're substantially greater. But even with your earnings, I agree it's an interesting situation. We're a tremendous growth company at a very low P.E. So besides having some great investment banks that we work with for which I am likely to do non-deal roadshows with institutional investors in the future. I also, as I mentioned, we work with Renmark. Lately, I've probably been conducting a virtual non-deal roadshow either once a week, once every other week. We actually had one scheduled for this week, but I didn't think it was appropriate to do that presentation the day before we reported earnings. So I believe we have a VNDR next week. And look, at the end of the day, we've been in a bear market for a year and a half. So as much as you can say that, and this is you, I can't say this, but you're saying that our stock is severely undervalued. I can simply point out that even though it's severely undervalued at today's prices, it's dramatically outperformed virtually every biotech and life science company over the last year plus, given that we've been in a significant bear market. It appears we're just coming out of that now. It doesn't mean we're not going to back and fill. But it's not just that the biotech and life science companies have trended higher over the last six to eight weeks. It's the fact that deals are starting to happen. And if deals are starting to happen, that sort of tells the marketplace if larger biotech and major pharmaceutical companies are acquiring the smaller biotech and life science companies, it's telling you that there's tremendous value Um, and that many of these stocks are oversold and undervalued now, um, regardless of what's going on with inflation and gas prices and the economy and, you know, wars around the world and everything else. So, um, I think I'm doing all the right things and, uh, to some extent, you know, it's, it's market dictated, but by the same token, we don't need capital. Um, and you know, we're generating enormous capital and I've always operated the company, um, from the point of view. We're going to build value on a per share basis. The stock price will take care of itself as long as we continue to build value. And that's what we've done over time. And that's why our stock has performed over the last decade. You know, we were 65 cents stock and now we've paid out $2 and 40 cents in dividends. And, you know, we have another 10, $11 stock. I mean, you know, our stock price up almost 20 times while paying out a significant amount of dividends. So as far as I'm concerned, we're doing all the right things and the stock price will take care of itself. if we continue to execute. And the businesses that we are working on now have enormous upside potential. I can't tell you on a month-to-month basis what's going to happen, but I can tell you that over the next year and a half, between the potential of Nebula and the potential of Prophase Biopharma, while diversifying our diagnostics business, there's still significant upside from where we are now. I can't guarantee what month, what quarter, But all the things we're working on, and what I like about it is the things we're working on, not only do they have enormous potential, but they have minimal downside risk. As I mentioned, all of our businesses take prophase biopharma out of the equation. Our other four businesses combined are all growing and generating significant cash flow. So the only business really at risk in terms of losing money is prophase biopharma, and I've said repeatedly now, Our budget's under $5 million. I think for a budget under $5 million, we potentially have a division that a year and a half from now could be worth literally hundreds of millions of dollars. So I look for opportunities with high reward and low risk. And in the case of Nebula, we're leveraging all their tremendous synergies. We're leveraging all the assets of the company, you know, between our distribution of food, drug, and mask stores, our distribution history of marketing consumer products, et cetera, et cetera, et cetera. And at ProPhase Biopharma, you know, interestingly, historically, we had a pharmaceutical division before, and unfortunately the management didn't do a great job of managing it. But I'm really excited. This has been in my blood for 40 years. I've always invested in biotech companies, and I think we're onto something big. I hope that answers your question, Dennis, and I appreciate you calling in.
Dennis Waldman
That answers the first part. Um, do you see other analysts picking us up besides the three that are covering us now?
Ted Karkas
Oh, look, it's possible. If I wanted to spend my time, um, calling on and investing, you know, one of the issues, um, with analysts, um, even though there is a wall between the analyst and the investment banker, um, you know, it gets, it gets a little complicated and I'm a, I'm a very loyal guy. And, uh, I like to believe that, well, look, I'm not really going to go there. The bottom line is, sure, I don't see why other analysts won't. Our performance is fantastic. And it's just a matter of how much time I want to spend marketing to new analysts to pick up coverage versus focusing on building the company. And where I think that my value, my time is best spent. And honestly, I'm more interested in building the value of the company. The stock price will take care of itself For short-term traders, I don't honestly care whether I disappoint short-term traders or not. I'm just looking to build the value of the company. We don't need capital right now. So we're in a great situation. If we get more coverage, great. Am I working on it? Yes, I would, but that's not where my full-time effort is going. And you want to actually watch out for management whose full-time effort is getting analyst coverage because all they're doing is promoting a worthless company. I'm doing the opposite. I'm building a valuable company. and then let the stock price and the coverage take care of itself.
Dennis Waldman
I understand. One final question. You've spoiled us with these incredible quarterly dividends. You had a great quarter, great cash flow, this Q2. Business still appears to be extremely strong, yet no dividend. Do we have to wait another quarter before finding out if there's going to be a dividend, or is there a chance we could see something sooner?
Ted Karkas
All right. So here's the deal. You actually just proved my point of my concern, which is that I don't want shareholders to expect a regular quarterly dividend. Also, it gets very complicated from an IRS point of view and a legal point of view if we start making it look like we pay a regular quarterly dividend every time we announce earnings. So, and truthfully, right now we're in a situation where we have an enormous amount of capital. It's growing. We certainly could pay a dividend, but at the same time, we also have a stock buyback in place, which we have not initiated yet. I don't think we're allowed to until a few days after we report earnings. And let's see if the shorts want to try and play games. And if they do, we're happy to buy all the stocks that they want to sell to us. So I'd like to see how the stock buyback goes. And at the same time, I don't want to create the perception that we pay a regular quarterly dividend. At the end of the day, we are a development stage life science company, and I have to manage the company prudently. Having said that, we certainly have the ability to pay more dividends in the future. I personally love dividends. I know that our shareholders love dividends. It's a way for all of us. to share in the success of the company together. So believe me, you know full well that I am motivated to pay dividends. I just want to be prudent about it, and I also don't want to do it as a regular quarterly dividend because then if we have a quarter where we don't pay a dividend, everybody gets upset, and, you know, everybody expects it. And I don't want to do it just because people expect it. And it doesn't matter to me whether we pay a dividend now or a month or two from now. All right, so does that answer your question? I'm not guaranteeing it.
Dennis Waldman
It does, Ted. No, that was great. Thank you. Thank you, and congratulations again.
Ted Karkas
Appreciate it. Next question, please.
Operator
The next question is from private investor Fred McDonald. Please go ahead.
Fred McDonald
Hey, Ted, great job. Hey, the university is studying the linebacker products. Do you know if their results will be publicized in a press release or a medical journal? And can you give us something to update what you're hearing?
Ted Karkas
Yeah. So that's actually a complicated situation because the university that did these preclinical studies, and I don't know how much I can get into this or not get into this, but because of certain agreements that were in place or that were not in place, made things a little complicated for publishing the results. That's why, actually, I believe the results could come out already. I can tell you that the university is so excited by the results they want to continue to do more research on linebacker one and two and in fact we just had a conference call with them uh yesterday um that went extremely well um and so there's a lot going on there um i would love to come out with a press release um talking about these results um honestly it wouldn't change anything from our our company point of view uh that we're still going to do all the same things but but then our shareholders would really understand why I'm so excited. And just for shareholders out there and for new shareholders, people that don't understand what linebacker one and two is and why I'm so excited about it. There's a growth factor that is present when you have cancer called PIM. I believe it's called PIM-123. And understand this in layman's terms, I'm explaining this to you. If you think about it logically, these growth factors are growing the cancer while you're taking drugs and chemotherapy and so forth to try and treat the cancer. So what if there was a compound out there that could inhibit the growth factor, the PIM, while you're giving the patient the other drug, therapy, or treatment to try and cure you of the cancer? If you think about it logically, you would think that the odds of the drug or chemotherapy or treatment will work better if the cancer the growth of the cancer is slowed down. That's exactly the theory behind linebacker one and two. So it has enormous potential as a co-therapy. Okay. We had an, we had an analyst poo poo at the, you know, as far as I'm concerned, didn't do a lot of, uh, research or pay attention or, you know, and basically, you know, said something, you know, it was pretty ignorant quite frankly. Um, but this has enormous potential. And so we have a university that, uh, a highly, regarded university, did significant work. It was like, oh, my God, this could be a major breakthrough in cancer. And so they're excited. They want to enter agreements. Now that we have the rights to this, they want to enter agreements with us directly to do a lot more work. And what we told them, though, is we don't want to give them royalties, but, you know, we'll collaborate with them and we'll hire them and they can have publication rights and they're excited to do that. And so that gives you kind of in very simplistic terms, what we're working with here. And so then I point to the fact that just last week, um, we had a, we had a company that was acquired for 400, $405 million, where all of their assets were either preclinical or one asset just going into phase one. And they're required for $405 million. So here we have something that could be a major breakthrough in cancer. We're going to be there as well as 18 months. So, um, You know, and so it's interesting, we announced the licensing of Live Backer and because of one analyst and what it did is it triggered Zach to go from a number one strong buy to, I guess, a number two buy. And it created, you know, profit taking and momentum, traders to sell the stock. And, you know, I guess there are probably algorithms and funds that sell the stock when you go from a one buy to two exact. So it triggered a domino effect, but that all seems to have played out its course. And so our response is, OK, we'll buy back stock. If there are going to be short-term games played with the stock, we'll buy back stock. So obviously, we believe the stock's undervalued to announce a stock buyback. And again, we don't need to raise capital now anyway. But it just gives you an idea of the enormity of the possibilities for what we're developing. And yes, it is very early stage. It is preclinical. But understand, it's preclinical where we also had Charles River, who's really Very well thought of scientific organization for clinical research organization for doing research. And they did, this didn't happen overnight. There's been enormous amount of preclinical work done on these compounds. And then we had a major university independent of them doing, conducting research that they're so excited about, they now want to collaborate with us in a longer term agreement. So there's just nothing but enormous upside. We paid virtually nothing for it. The first time we have to pay a significant milestone is phase three. I would expect, you know, it would not surprise me if a major pharma, if we got to phase three, a major pharma, you know, we're all going to be able to retire on this if we get to phase three. All right. You know, we're like, this is going to be a joke. It's, you know, $10. Are you kidding me? We're going to be looking at it, you know. Anyway, I don't want to go there. I think I said more than enough, and I think I answered your question. It was a great question. Thank you.
Fred McDonald
Hey, Ted, one more question. Do you have any idea when the university study will be completed?
Ted Karkas
Yeah, so I believe it was completed, but as I said, and Yichen asked that question, it's complicated. because the agreement was not with our company, and I don't know if the appropriate agreements were in place for them to be able to publish the study. So there's a complicated issue. I actually believe the preclinical study that they did is completed, and that's why they want to continue. They want to do more studies. And so I don't know if we're going to be able to publish it or not or when. We're going to sort that all out. I don't have more details now. We just did a conference call with them yesterday. So it went extremely well. So I can tell you it's all systems go on development of Linebacker 1 and 2. And the work that's been done to date has shown truly very promising results.
Fred McDonald
Thank you.
Ted Karkas
You're quite welcome.
Operator
Pardon me. The next question comes from Patrick E. Patterson, private investor. Please go ahead.
Ken
He's back. Okay, Ken. Tim, thanks for taking me back. Sorry I lost you there. But my question is probably the most boring one you're going to have today, but it's one I'm interested in. You know, I follow Quest and I follow LabCorp. They're billion-dollar companies. They're in the clinical lab diagnostic testing, traditional blood and urine, that sort of thing. And you've been talking about expanding and you're going into there. And I just know you wouldn't be doing that unless you knew where your customers were going to come from. Can you share some info on us and where your customers come from?
Ted Karkas
That's a great question. So here's the best way I can answer that. First of all, everybody told us a year and a half ago that we, how are we going to compete with LabCorp and Quest? Have they affected us by even one penny? Could you imagine we're a startup company? Find me another startup company. all right, that in the last nine months, a complete startup that just generated $43 million in EBITDA and 100 and whatever, approximately over 120 million in revenues. All right, so this is the last three quarters. Tell me a startup company that you've ever come across in your life that in its first year in operation generated those kinds of numbers. So does LabCorp or Quest affect us by even a penny? All right, second of all, as I've explained, Their IT infrastructure, they've been in business a long time. Their equipment is older. Yes, they can buy new equipment and they can build new IT, but you also have to understand that they're not all of a sudden, all their customers are already locked into their old IT infrastructure. They're already doing business very efficiently with their equipment. We built a state-of-the-art lab with all new equipment and an IT platform that is custom made and developed and sophisticated based on the way business is being done today. So as far as I'm concerned, our IT platform, our equipment, it's as sophisticated, as efficient as anybody out there. And I do know for a fact that the way we process certainly COVID specimens, we're one of the lowest cost, most efficient processors of specimens. And that's why we haven't lost a customer. None of our customers have gone to those big labs. They get screwed over by the big labs every time they go over to them. So separate from that now, that doesn't really answer your question. Interestingly, I just had meetings the other day. There are lots of people in this world, very connected people that are capable of bringing business wherever they want to bring business to. And it's much more attractive to them to work with a company like ours that's more entrepreneurial, that will work closely with them. I mean, could you imagine if you're, I don't know, you have the ability to send 20 nursing homes to do their clinical lab testing to a lab? Could you imagine saying to yourself, hmm, why don't I call Quest? Now, who am I gonna call at Quest? Am I gonna be able to talk to the CEO of Quest? Am I going to be able to talk to the president of Quest? Am I going to be able to talk to an executive that's two levels below? Probably not. All right. You come to our company. You can work with us. Really, you're working with Jason. You're working with me. And yet we're meeting with high-level people. There's enormous potential. And, look, at the end of the day, again, you're betting on the jockey. You're betting on the management team. Um, we've executed for more than a decade and more recently we've executed the lab business over the last two years. So now we're entering a clinical lab business. Um, if you want to bet against us executing, you know, by all means, but I don't know logically why anybody would assume that we're not going to be able to execute. I would say just the opposite. Um, until proven otherwise, you should assume that we will execute. I can't give you a better answer than that because it's not like all of a sudden we have, you know, it's a chicken or egg situation. Nobody's going to commit. to bringing us a large amount of business before we have the lab fully set up and operational. And so it's a chicken or egg situation. There's a small possibility that I could buy a small lab, not a big lab that's going to cripple us, but a small lab that gives us everything turnkey. And if I see that we have customers with significant potential, And I can align that with acquiring a lab so we can really jumpstart this. I will do that. So I just want you to know we're working a number of different angles. We have to see how it all plays out. Again, I've mentioned previously, I've probably looked at 60 lab acquisitions over the past year. We're so spoiled by our own lab. I didn't like any of them. But having said that, there may be an opportunity that comes along. And if there is, maybe we'll buy a lab which would have a customer business and have all the licenses and insurances. But at the same time, One of the reasons I would be motivated to do that is because we're currently actually talking to people who could bring us an enormous amount of business. So it's a chicken or egg, but you've got to understand, the same way we executed on building our lab business, you know, at lightning speed, there's no reason not to believe that we're not going to execute on our clinical lab business. And it's going to happen when it happens. And, you know, we might have growing pains for a quarter or two, but I expect to build a very valuable business. the same way that I and we have done over the last decade or so. I hope that answers your question. It was a good question.
Ken
No, thank you very much, Dan. I appreciate it. You guys did a great job. Great job.
Ted Karkas
All right. Thank you. Pat, always appreciate your support. I think, and if I go back to our moderator, are there any other questions?
Operator
At this time, there are no more questions in the queue.
Ted Karkas
Okay. So then I would just like to thank all of our shareholders, our analysts, our investment bankers, and potential investors. I want to thank you all for spending the hour with me. You know, I have a running joke that I love to talk, and here's a situation where I get to talk and nobody gets to interrupt me. I like to think that what we're talking about is all really exciting and really positive. You know, honestly, I've never been more excited about our company and the future of our company. And I'm not talking about, you know, over the next month or two, but over the next 12 to 18 to 24 months, you could see some dramatic changes. It's not a guarantee, but you could see some dramatically positive upside in virtually every subsidiary we're working on. And in the meantime, you know, the risk, frankly, is pretty minimal given that, Our four operating businesses, you know, as a whole are growing year over year and very profitable. And our fifth one, our biopharma division, has probably more upside than anything else we're working on. And, you know, the amount of capital in my mind, it's virtually a rounding error what we're going to spend to develop it. So I think we're well situated for the future, and I appreciate everyone's attention and continued support. Have a great day.
Operator
The conference is now concluded. Thank you for your participation. You may now disconnect.
Disclaimer